- $266.60m
- $221.94m
- €0.03m
U.S. STOCKS ON THE MOVE-Boeing, Skechers, Microsoft, JC Penney
U.S. STOCKS ON THE MOVE-Microsoft, Skechers, CIRCOR
Inflarx shares jump on new analysis of skin disease drug trial
Brief: InflaRx Reports Additional Analysis Of The SHINE Phase IIb Results For IFX-1 In Hidradenitis Suppurativa
U.S. STOCKS ON THE MOVE-AMD, Dupont, Ciena, At Home Group
InflaRx: Fails to "shine", brokerages cut to single-digit PTs
U.S. STOCKS ON THE MOVE-Apple, American Eagle Outfitters, Microsoft, GameStop, ReWalk
U.S. STOCKS ON THE MOVE-Apple, American Eagle Outfitters, Microsoft, GameStop, ReWalk
U.S. STOCKS ON THE MOVE-Apple, McDermott, American Eagle, GameStop, ReWalk
Brief: Inflarx Announces Top-Line Shine Phase IIb Results For IFX-1 In Hidradenitis Suppurativa
InflaRx: Slides after flaky results; pulls down ChemoCentryx
Brief: Inflarx NV Files For Potential Mixed Shelf Offering; Size Not Disclosed
Brief: Inflarx NV Had Cash & Cash Equivalents & Securities & Other Investments Of EUR 156.6 Mln As Of Dec. 31, 2018
Brief: Inflarx Receives Approval To Initiate Phase IIa Clinical Trial
Sage Therapeutics: Guggenheim's favorite among 11 biotechs
Brief: Inflarx Announces Presentation Of New Clinical Data With Lead Candidate Ifx-1 In Hidradenitis Suppurativa
U.S. RESEARCH ROUNDUP-CNX Midstream Partners, Intuit, Ultimate Software Group
Atara, Inflarx are JPMorgan's top-picks among small biotechs
Brief: Inflarx NV Receives European Approval To Initiate Phase II Clinical Trial With IFX-1